GGrantIndex
← Leaderboards

Janice B Schwartz

Northwestern University

$4,527,322
Attributed
$4,797,616
Total exposure
11
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $780.6K · FY200522
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$4,327,229 · 10
FDA$470,387 · 1

By mechanism

R01$2,220,865 · 2
R21$980,423 · 2
RC1$831,981 · 1
U01$470,387 · 1
R56$225,000 · 1
M01$68,960 · 4

Top collaborators

Most similar at Northwestern University

Same institution · by research overlap

Others in their field

Top investigators on “Elderly

Research focus

ElderlyAgingPharmaceutical PreparationsVerapamilWomanOralInvestigationCharacteristicsOlder PatientDrug MetabolismDosageDrug ClearanceHuman SubjectAmlodipineNursing HomesCytochrome P450AlgorithmsClearance RateCyp3a4 GeneMedicalGender DifferenceClinical ResearchDrug KineticsKidney

Grant awards (27)

The study: LatinX/HIspanic Attitudes and Perspectives on Investigations and Studies- of New Drugs: LAPIS-ND$470,387
U01 · FY2022 · FD · contact PI
Direct-Acting Oral Anticoagulants: Anticoagulant Activity in Understudied Older NVAF Patients$161,500
R21 · FY2021 · AG · contact PI
Supplement to Direct-Acting Oral Anticoagulants: Anticoagulant Activity in Understudied Older NVAF Patients$96,900
R21 · FY2021 · AG · contact PI
Direct-Acting Oral Anticoagulants: Anticoagulant Activity in Understudied Older NVAF Patients$282,188
R21 · FY2020 · AG · contact PI
Optimizing vitamin D in the elderly$148,444
R21 · FY2013 · AG · contact PI
Optimizing vitamin D in the elderly$69,141
R21 · FY2013 · AG · contact PI
Optimizing vitamin D in the elderly$222,250
R21 · FY2012 · AG · contact PI
Improving Medication Therapy for Older Patients with Common Co-morbidities$417,338
RC1 · FY2010 · AG · contact PI
Older Persons & Drugs: race, gender, and age effects$225,000
R56 · FY2010 · AG · contact PI
Improving Medication Therapy for Older Patients with Common Co-morbidities$414,643
RC1 · FY2009 · AG · contact PI
Older Persons & Drugs: race, gender, and age effects$237,462
R01 · FY2009 · AG · contact PI
Older Persons & Drugs: race, gender, and age effects$128,500
R01 · FY2009 · AG · contact PI
Older Persons & Drugs: race, gender, and age effects$236,296
R01 · FY2008 · AG · contact PI
Older Persons & Drugs: race, gender, and age effects$239,965
R01 · FY2007 · AG · contact PI
Older Persons & Drugs: race, gender, and age effects$245,978
R01 · FY2006 · AG · contact PI
Older Persons &Drugs: race, gender, and age effects$250,750
R01 · FY2005 · AG
OLDER PERSONS AND DRUGS: RACE, GENDER AND AGE EFFECTS$936
M01 · FY2005 · RR
Older Persons &Drugs: Race, Gender &Age Effects$27,076
M01 · FY2004 · RR
OLDER PERSONS AND DRUGS--RACE, GENDER, AND AGE EFFECTS$223,171
R01 · FY2003 · AG
OLDER PERSONS AND DRUGS--RACE, GENDER, AND AGE EFFECTS$217,606
R01 · FY2002 · AG
OLDER PERSONS AND DRUGS--RACE, GENDER, AND AGE EFFECTS$212,179
R01 · FY2001 · AG
EFFECTS OF AGING AND GENDER ON CYTOCHROME P450 ACTIVITY--SUSTAINED RELEASE DOSE$0
M01 · FY2001 · RR
OLDER PERSONS AND DRUGS--RACE, GENDER, AND AGE EFFECTS$206,891
R01 · FY2000 · AG
CARDIOPULMONARY TIME SERIES ANALYSIS--DRUG AND AGING EFFECTS$22,067
R01 · FY2000 · GM
EFFECT OF AGING AND GENDER ON CYTOCHROME P450 ACTIVITY$20,474
M01 · FY2000 · RR
OLDER PERSONS AND DRUGS--CALCIUM BLOCKER KINETICS/DYNAMICS$20,474
M01 · FY2000 · RR
EFFECTS OF AGING AND GENDER ON CYTOCHROME P450 ACTIVITY--SUSTAINED RELEASE DOSE$0
M01 · FY2000 · RR